Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.75 USD
-0.08 (-2.83%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $2.72 -0.03 (-1.09%) 4:34 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELDN 2.75 -0.08(-2.83%)
Will ELDN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELDN
Are Medical Stocks Lagging DaVita (DVA) This Year?
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ELDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ELDN
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Eledon Pharmaceuticals (ELDN) and Abbott Laboratories (ABT)